RT Journal Article
T1 Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.
A1 Roy-Vallejo, Emilia
A1 Sanchez-Purificacion, Aquilino
A1 Torres-Peña, Jose David
A1 Sanchez-Moreno, Beatriz
A1 Arnalich, Francisco
A1 Garcia-Blanco, Maria Jose
A1 Lopez-Miranda, Jose
A1 Romero-Cabrera, Juan Luis
A1 Herrero Gil, Carmen Rosario
A1 Bascunana, Jose
A1 Rubio-Rivas, Manuel
A1 Pintos-Otero, Sara
A1 Martinez-Sempere, Veronica
A1 Ballano-Rodriguez-Solis, Jesus
A1 Gil-Sanchez, Ricardo
A1 Luque-Del-Pino, Jairo
A1 Gonzalez-Noya, Amara
A1 Navas-Alcantara, Maria Sierra
A1 Cortes-Rodriguez, Begoña
A1 Alcala, Jose Nicolas
A1 Suarez-Lombraña, Ana
A1 Andres-Soler, Jorge
A1 Gomez-Huelgas, Ricardo
A1 Casas-Rojo, Jose Manuel
A1 Millan-Nuñez-Cortes, Jesus
K1 ACEI
K1 ARB
K1 COVID-19
K1 MACE
K1 prognosis
AB Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63–0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62–0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.
PB MDPI AG
SN 2077-0383
YR 2021
FD 2021-06-11
LK http://hdl.handle.net/10668/18098
UL http://hdl.handle.net/10668/18098
LA en
NO Roy-Vallejo E, Sánchez Purificación A, Torres Peña JD, Sánchez Moreno B, Arnalich F, García Blanco MJ, et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. J Clin Med. 2021 Jun 15;10(12):2642.
DS RISalud
RD Apr 6, 2025